By analyzing existing basic indicators between Artelo Biosciences and Aadi Bioscience, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Aadi Bioscience with a short position in Artelo Biosciences. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
One of the ways to look at asset utilization of Artelo is to check how much profit was generated for every dollar of assets it reports. Artelo Biosciences shows a negative utilization of assets of -0.28 percent, losing $0.002775 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Artelo Biosciences shows how discouraging it operates for each dollar spent on its assets.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as Artelo or Salarius is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is Artelo Biosciences's Liquidity
Artelo Biosciences
financial leverage refers to using borrowed capital as a funding source to finance Artelo Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Artelo Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Artelo Biosciences' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Artelo Biosciences' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Artelo Biosciences's total debt and its cash.
Correlation Between Artelo and Salarius Pharmaceuticals
In general, Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Artelo Biosciences together with similar or unrelated positions with a negative correlation. For example, you can also add Salarius Pharmaceuticals to your portfolio. If Salarius Pharmaceuticals is not perfectly correlated to Artelo Biosciences it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Artelo Biosciences, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both Artelo Biosciences and Salarius Pharmaceuticals in your portfolio? Please note if you are using this as a pair-trade strategy between Artelo Biosciences and Salarius Pharmaceuticals, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between ARTL and SLRX for more information.
Detailed Perspective On Artelo Biosciences
Cash and Equivalents Breakdown
Let me take a closer look at Artelo Biosciences cash and equivalents. In accordance with the recently published financial statements, Artelo Biosciences has 21.32
M in Cash and Equivalents. This is 97.4% lower than that of the Pharmaceuticals sector and 95.23% lower than that of the
Health Care industry. The cash and equivalents for all United States stocks is 99.21% higher than that of the company. As for Aadi Bioscience we see cash and equivalents of 118.74
M, which is 73.44% lower than that of the Health Care
| ARTL | 21.32 Million | 3.63 |
| Sector | 447.12 Million | 76.15 |
| AADI | 118.74 Million | 20.22 |
Another small slide for Artelo Biosciences
Latest coefficient of variation is at 973.34.
As of the 27th of February, Artelo Biosciences shows the Downside Deviation of 2.73,
risk adjusted performance of 0.1016, and Mean Deviation of 2.49. Artelo Biosciences
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen
technical drivers for Artelo Biosciences, which can be compared to its rivals. Please confirm
Artelo Biosciences variance,
value at risk, as well as the
relationship between the Value At Risk and
skewness to decide if Artelo Biosciences is priced correctly, providing market reflects its regular price of 2.87 per share. Please also double-check Artelo Biosciences
total risk alpha, which is currently at 0.4521 to validate the company can sustain itself at a future point.
The Current Takeaway on Artelo Biosciences Investment
Whereas some other companies in the biotechnology industry are either recovering or due for a correction, Artelo Biosciences may not be performing as strong as the other in terms of long-term growth potentials. With an optimistic outlook on your 90 days horizon, it may be a good time to take in new shares of Artelo or increase your existing holdings in the Stock as it seems the potential growth has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Artelo Biosciences.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Aina Ster is a Member of Macroaxis Editorial Board. Aina delivers weekly perspective on ongoing market and economic trends, analysis and tips from predictive analysis to forecasting across various financial instruments.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Artelo Biosciences. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
